Key facts
- This page summarizes Shannon Shoemaker's Form 4 filing for PSYCHEMEDICS CORP (PMDI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Sep 2023, 18:29.
Shannon Shoemaker - 21 Sep 2023 Form 4 Insider Report for PSYCHEMEDICS CORP (PMDI)
- Reporting relationship
- Chief Revenue Officer
- Issuer ticker
- PMDI
- Reported as of
- 21 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Sep 2023, 18:29:55 UTC
- Prior SEC filing
- 25 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- Patrick J. Kinney, Jr. as attorney-in-fact for Shannon Shoemaker
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shannon Shoemaker filed Form 4 for PSYCHEMEDICS CORP (PMDI) on 25 Sep 2023.
Change
- Previous filing in this sequence was filed on 25 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 21 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 40,000
- Exercise price
- $3.66
- Footnotes
- F1
PMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 21 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock, $.005 Par Value
- Underlying amount
- 80,000
- Exercise price
- $3.66
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option becomes exercisable with respect to 50% of the shares on September 18, 2024 and with respect to the remaining 50% on September 18, 2025.
Footnote F2
The option becomes exercisable, if at all, in two 40,000 share increments. The first increment of 40,000 shares becomes exercisable at the time the weighted average daily price of Psychemedics common stock on the Nasdaq Stock Market during any consecutive 60 calendar day period ending on or before September 21, 2026 shall have exceeded $5.50. The second increment of 40,000 shares becomes exercisable at the time the weighted average daily price of Psychemedics common stock on the Nasdaq Stock Market during any consecutive 60 calendar day period ending on or before September 21, 2027 shall have exceeded $6.50.